CK Life Sciences Intl (Holdings) Inc
HKEX:775
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (22.1), the stock would be worth HK$-0.1 (114% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -161.9 | HK$0.75 |
0%
|
| 3-Year Average | 22.1 | HK$-0.1 |
-114%
|
| 5-Year Average | 24.4 | HK$-0.11 |
-115%
|
| Industry Average | 6.5 | HK$-0.03 |
-104%
|
| Country Average | 9.6 | HK$-0.04 |
-106%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| HK |
|
CK Life Sciences Intl (Holdings) Inc
HKEX:775
|
7.2B HKD | -161.9 | -38.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
355.3B USD | 14.1 | 84.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.9B USD | 14.1 | 24.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.8B USD | 12.2 | 19.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.5B USD | 21 | 28 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81B USD | 13.4 | 18 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR | 41.5 | 38.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.2B AUD | 10.3 | 30.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 4.8 |
| Median | 9.6 |
| 70th Percentile | 14.9 |
| Max | 9 749.3 |
Other Multiples
CK Life Sciences Intl (Holdings) Inc
Glance View
CK Life Sciences International (Holdings), Inc. operates as an investment company, which engages in the business of research and development, manufacturing, commercialization, marketing and selling of products and assets in nutraceuticals, pharmaceuticals and agriculture related business. The company employs 1,855 full-time employees The company went IPO on 2002-07-16. The firm operates through three segments. The Health segment is engaged in the development, production, marketing and sales of healthcare and pharmaceutical products. The healthcare brands under the Company include Lipa, Vitaquest and Sante Naturelle, among others. Its pharmaceutical products include cancer-related pharmaceuticals and painkillers, among others. The Agriculture-related Businesses segment is engaged in the operation of vineyards, as well as the development, production, marketing and sales of agriculture and related products. Its agricultural products include fertilizers and crop protection products, among others. The Investment segment is engaged in the investment in financial and investment products.
